U.S. Logistics Stock News

NasdaqCM:RGTI
NasdaqCM:RGTISemiconductor

Rigetti Computing (RGTI) Valuation Check As Q4 2025 Results And Cepheus Launch Delay Draw Investor Focus

Rigetti Computing (RGTI) is drawing fresh attention as its March 4 fourth quarter 2025 earnings report approaches, with investors focused on revenue, Remaining Performance Obligations, and guidance after the postponed Cepheus-1-108Q launch. See our latest analysis for Rigetti Computing. At a share price of $17.69, Rigetti has seen short term pressure, with a 90 day share price return of 25.92% decline and a year to date share price return of 25.04% decline. This comes even though the 1 year...
NYSE:IVZ
NYSE:IVZCapital Markets

Is Invesco’s Expanded Buybacks And Alternatives Push Quietly Recasting Its Capital Allocation Story (IVZ)?

In late February 2026, Invesco Ltd. launched the Invesco Core Plus Real Estate Trust for defined contribution plans and four new fixed-income ETFs, while also lifting its share repurchase authorization to US$2.50 billion and declaring dividends across its closed-end fund lineup. Together with SEC approval for dual share classes and survey data showing strong participant interest in private markets, these moves highlight Invesco’s push to widen retirement access to alternatives and deepen its...
NYSE:PARR
NYSE:PARROil and Gas

Par Pacific Balances Record Refining, Renewables Push And Shareholder Returns

Par Pacific Holdings (NYSE:PARR) reported record refining throughput in 2025, including recovery from an earlier operational issue at its Wyoming refinery. The company recorded a substantial gain tied to an EPA small refinery exemption in 2025. Par Pacific launched the Hawaii Renewables joint venture and advanced plans for a renewable fuels facility in 2025. The company carried out a major share repurchase in 2025, highlighting a focus on shareholder returns. Par Pacific Holdings, the...
NasdaqGS:TFSL
NasdaqGS:TFSLBanks

Is TFS Financial (TFSL) Pricing In Too Much Optimism After Recent Regional Bank Focus?

If you are wondering whether TFS Financial is offering fair value at today’s price, you are not alone. This article is designed to help you weigh what the current share price might be implying. The stock most recently closed at US$14.33, with returns of 0.8% over 7 days, 1.8% over 30 days, 5.6% year to date, 17.9% over 1 year, 31.8% over 3 years and a 2.6% decline over 5 years. Recent news around TFS Financial has focused on its position as a regional bank and its role in the broader US...
NYSE:WH
NYSE:WHHospitality

A Look At Wyndham Hotels & Resorts (WH) Valuation After Recent Share Price Swings

What Wyndham Hotels & Resorts stock’s recent performance tells you Wyndham Hotels & Resorts (WH) has seen mixed share performance recently, with a 1 day return of about a 1.6% decline and a 7 day move of roughly a 3.1% decline. Over the past month and past 3 months, the stock shows positive returns of about 10.6% and 10.2%, while the 1 year total return sits around a 22.7% decline, giving investors a mixed picture. See our latest analysis for Wyndham Hotels & Resorts. At a share price of...
NYSE:GWRE
NYSE:GWRESoftware

Guidewire Software (GWRE) Valuation Check After Sompo Cloud Deal And Supportive AI Sentiment

Guidewire Software (GWRE) is back in focus after Sompo Group agreed to roll out Guidewire Cloud Platform across its global and Japanese insurance operations, while recent AI commentary has also supported sentiment around enterprise software providers. See our latest analysis for Guidewire Software. The Sompo cloud rollout and supportive AI commentary arrive after a sharp near term rebound, with a 7 day share price return of 21.92%, set against a softer 90 day share price return of 30.60%...
NYSE:CBZ
NYSE:CBZProfessional Services

Is It Time To Reconsider CBIZ (CBZ) After A 62.5% One-Year Share Price Slump?

If you are wondering whether CBIZ at around US$28.80 is starting to look interesting, the key question is whether the market is underestimating or fairly reflecting its underlying worth. The share price has moved around recently, with a 4.0% gain over the last 7 days, set against a 26.8% decline over 30 days and a 62.5% decline over 1 year. This can change how investors view both its potential and its risk. These moves are landing in a period where investors are reacting to ongoing corporate...
NasdaqGS:INSM
NasdaqGS:INSMBiotechs

Insmed’s BRINSUPRI Outperformance Puts Commercial Execution And Valuation In Focus

Insmed reported that the US commercial launch of BRINSUPRI has exceeded internal expectations. On the back of this outperformance, the company plans to accelerate and broaden BRINSUPRI’s rollout across the US market. Insmed also intends to further grow ARIKAYCE in 2026, signaling an updated product commercialization plan beyond routine quarterly results. For investors watching Insmed (NasdaqGS:INSM), the BRINSUPRI update comes after a sharp share price move over the past year. The stock...
NYSE:AMCR
NYSE:AMCRPackaging

Is Amcor (AMCR) Still Offering Value After Mixed Recent Share Price Performance

If you are wondering whether Amcor's recent share price moves still leave value on the table, you are not alone. This article is aimed at helping you weigh that up clearly. Over the short term, the stock has had a 4.8% decline over 7 days, but an 8.8% return over 30 days and a 14.5% return year to date, with a 0.7% return over 1 year, 2.1% over 3 years and 3.9% over 5 years. Taken together, these figures give a mixed picture of momentum and risk sentiment. This article was prompted to keep...
NYSE:DKL
NYSE:DKLOil and Gas

How Investors Are Reacting To Delek Logistics Partners (DKL) Record EBITDA And Libby 2 Expansion

In late February 2026, Delek Logistics Partners, LP reported full-year 2025 results showing revenue of US$1,013.32 million and net income of US$176.46 million, alongside record adjusted EBITDA of US$536 million and the commissioning of its Libby 2 gas processing plant. The partnership also marked its 52nd consecutive quarterly distribution increase and highlighted the growing contribution of its integrated crude, gas, and water midstream platform in the Permian Basin. We’ll now examine how...
NasdaqGS:KMB
NasdaqGS:KMBHousehold Products

Does Kotex’s Gravity Core Relaunch Signal a Deeper Pivot Toward Premiumization at Kimberly-Clark (KMB)?

In February 2026, Kimberly-Clark’s Kotex brand launched a fully reimagined range of pads and liners, introducing Gravity™ Core technology, a 5X System with LeakShield™, new BioCare and Bamboo lines, teen-focused and overnight products, and a bold visual identity, with nationwide US rollout across major retailers. This portfolio overhaul directly targets widespread consumer frustration with existing period products, aiming to differentiate Kotex through comfort-focused materials, odor and pH...
NasdaqGM:FIVN
NasdaqGM:FIVNSoftware

Five9 (FIVN) Valuation Check After Strong Earnings And Expanding Enterprise AI Outlook

Five9 (FIVN) is back in focus after reporting Q4 and full year 2025 results, issuing 2026 guidance, and spotlighting enterprise AI growth that now exceeds a US$100 million annual run rate. See our latest analysis for Five9. Despite the earnings beat and fresh 2026 guidance, Five9’s recent 90 day share price return decline of 11.27% and 1 year total shareholder return decline of 49.33% suggest momentum has been under pressure, even as enterprise AI becomes a larger part of the story. If this...
NYSE:AMBP
NYSE:AMBPPackaging

A Look At Ardagh Metal Packaging (AMBP) Valuation After Earnings Beat, Green Bond Refi And Dividend Update

Ardagh Metal Packaging (AMBP) has given investors plenty to think about after reporting 2025 results that exceeded its own guidance, outlining 2026 adjusted EBITDA growth expectations, completing a US$1.3b green bond refinancing, and affirming a quarterly dividend. See our latest analysis for Ardagh Metal Packaging. The recent earnings beat, 2026 EBITDA guidance and US$1.3b green bond refinancing sit against a share price of US$4.85, with a 30 day share price return of 10.48% and a 1 year...
NasdaqGS:GENB
NasdaqGS:GENBBiotechs

Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility

Event overview and immediate context Generate Biomedicines (GENB) recently drew investor attention after a single day move of about 3.8% and a year to date return of roughly a 23.9% decline, prompting closer scrutiny of its drug discovery model and early stage pipeline. See our latest analysis for Generate Biomedicines. For now, the 1 day share price return of about 3.8% and year to date share price return of roughly a 23.9% decline suggest sentiment has cooled, even as interest in its...
NYSE:AXP
NYSE:AXPConsumer Finance

Is American Express (AXP) Still Attractive After Recent Share Price Pullback?

If you are wondering whether American Express shares still offer value at current levels, this article will walk through what the numbers suggest and how that might fit your own expectations. The stock last closed at US$307.43, with returns of 5.1% over 1 year, 78.0% over 3 years and 117.3% over 5 years. The shorter term picture shows a 4.3% decline over 7 days, a 12.7% decline over 30 days and a 17.5% decline year to date. Recent headlines around American Express have kept attention on the...
NYSE:LCII
NYSE:LCIIAuto Components

LCI Industries Leans On Acquisitions To Broaden Growth Beyond RV Cycle

LCI Industries (NYSE:LCII) has signaled ongoing interest in acquisitions, highlighting a renewed focus on M&A within its core markets. The company referenced a history of completed deals and expressed intentions to build on recent M&A momentum. This more active approach to acquisitions could influence LCI Industries' growth path, competitive position and capital deployment priorities. For investors watching NYSE:LCII, the renewed emphasis on acquisitions comes as the shares trade at...
ARCA:ESBA
ARCA:ESBAREITs

Empire State Realty OP (ESBA) FFO Loss Challenges Bullish Narratives After FY 2025 Results

Empire State Realty OP (ESBA) just wrapped up FY 2025 with Q4 total revenue of US$199.7 million and basic EPS of US$0.13, while trailing twelve month revenue sits at US$768.3 million and EPS at US$0.27. Over the past few quarters, revenue has moved from US$197.6 million in Q4 2024 to US$199.7 million in Q4 2025, with quarterly EPS shifting from US$0.07 to US$0.13. This sets up a picture where investors will be weighing these earnings against a 9.5% net margin and the impact of a one off gain...
NasdaqGS:WIX
NasdaqGS:WIXIT

A Look At Wix.com (WIX) Valuation As Earnings Approach And New AI Tools Roll Out

Wix.com (WIX) is back in focus as investors position ahead of its March 4 earnings release, while the company rolls out new AI powered tools and integrations with Google and Intuit that aim to deepen its role in online commerce. See our latest analysis for Wix.com. With the share price at US$72.56, Wix.com has seen a 2.98% 1 day share price return and a 15.54% 7 day share price return, but a 24.31% 90 day share price decline and a 61.68% 1 year total shareholder return decline suggest...
NYSE:KR
NYSE:KRConsumer Retailing

Is It Too Late To Consider Kroger (KR) After Strong Multi Year Share Price Gains?

Investors may be wondering whether Kroger, at around its recent US$69.05 close, is still a reasonable entry point or if most of the easy value is already on the table. The stock has returned 1.2% over the last 7 days, 9.9% over the past month, 9.7% year to date, 12.0% over 1 year, 58.7% over 3 years and 121.0% over 5 years. These returns may have shifted how the market views its risk and return trade off. Recent coverage has focused on Kroger's ongoing position as a major US grocery chain...
NYSE:PGR
NYSE:PGRInsurance

How Progressive’s Stronger Margins and Digital Push Will Impact Progressive (PGR) Investors

In recent months, Progressive reported higher net premiums written and earned, stronger underwriting margins with an improved combined ratio, and broad policy growth across personal, commercial, and property lines. An interesting angle is how its push into digital and direct-to-consumer channels appears to be amplifying this operational momentum across the entire franchise. Next, we’ll examine how this improved combined ratio and premium growth may influence Progressive’s existing investment...
NYSE:ASA
NYSE:ASACapital Markets

Assessing ASA Gold and Precious Metals (ASA) Valuation After Saba Capital’s Updated Activist Proposal

Activist pressure puts ASA Gold and Precious Metals in focus Saba Capital Management LP has urged ASA Gold and Precious Metals (ASA) to conduct a comprehensive review, with an updated February 19 presentation outlining clarified alternatives for the Board to evaluate. For you as an investor, this kind of activist communication often raises questions around portfolio structure, capital allocation and potential changes that could affect how ASA trades relative to its underlying precious metals...
NYSE:GE
NYSE:GEAerospace & Defense

Does GE’s Growing Role in Unmanned Propulsion Quietly Reshape the Bull Case for General Electric (GE)?

In February 2026, Kratos Defense & Security Solutions announced a US$12.40 million U.S. Air Force contract with GE Aerospace to complete preliminary design work on the GEK1500 next-generation 1,500‑lb thrust engine for small collaborative combat aircraft and unmanned systems, while Starfighters Space moved its STARLAUNCH 1 rocket program into Critical Design Review with GE Aerospace support. Together, these projects highlight GE Aerospace’s expanding role in affordable, high-performance...
NYSE:MET
NYSE:METInsurance

Is MetLife (MET) Pricing Look Attractive After Recent Share Price Weakness?

If you are wondering whether MetLife’s current share price reflects its true worth, this article explains how the market might be pricing the stock today. MetLife last closed at US$73.24, with returns of a 2.7% decline over 7 days, a 7.2% decline over 30 days, an 8.8% decline year to date, and a 12.0% decline over 1 year, compared with gains of 15.3% over 3 years and 41.2% over 5 years. These mixed returns sit against a backdrop of ongoing news coverage around the company’s position as a...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative?

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation. Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...